Shares of Smith & Nephew plc (LON:SN - Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 1,026.32 ($13.87) and traded as high as GBX 1,080 ($14.59). Smith & Nephew shares last traded at GBX 1,061 ($14.34), with a volume of 1,689,118 shares.
Smith & Nephew Trading Up 0.9%
The company has a market capitalization of £11.76 billion, a price-to-earnings ratio of 38.61, a P/E/G ratio of 0.46 and a beta of 0.62. The company has a current ratio of 2.51, a quick ratio of 0.84 and a debt-to-equity ratio of 70.22. The business's 50 day moving average price is GBX 1,039.63 and its two-hundred day moving average price is GBX 1,028.57.
Insider Buying and Selling
In other Smith & Nephew news, insider Sybella Stanley purchased 3,810 shares of the business's stock in a transaction dated Wednesday, March 26th. The shares were bought at an average price of GBX 1,101 ($14.88) per share, for a total transaction of £41,948.10 ($56,686.62). Also, insider Jeremy (Jez) Maiden acquired 1,855 shares of the firm's stock in a transaction that occurred on Thursday, May 1st. The stock was bought at an average price of GBX 1,070 ($14.46) per share, with a total value of £19,848.50 ($26,822.30). 0.19% of the stock is owned by corporate insiders.
Smith & Nephew Company Profile
(
Get Free Report)
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Featured Articles
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
